Biogen Inc. (BIIB)
Healthcare • Drug Manufacturers - General
StockNasdaqGSUnited StatesUS09062X1037
251.60 USD
+0.45% today Updated 13 Nov 2026 16:08
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Biogen Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:08. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
05 Feb 2027
in 84 days · 08:00 · estimate 2.82
Last results
2.62 vs 1.99 estimated
28 Oct 2026 · Beat +31.5%
Beat the estimate
11 of 12
1 missed · 0 in line · 11 beats in a row
Average surprise
+21.9%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 05 Feb 2027 08:00 | 2.82 | — | — | Upcoming |
| 28 Oct 2026 06:00 | 1.99 | 2.62 | +31.5% | Beat |
| 29 Jul 2026 06:00 | 2.03 | 3.60 | +77.4% | Beat |
| 29 Apr 2026 06:00 | 2.89 | 3.57 | +23.6% | Beat |
| 06 Feb 2026 06:00 | 1.62 | 1.99 | +23.2% | Beat |
| 30 Oct 2025 06:00 | 3.88 | 4.81 | +23.9% | Beat |
| 31 Jul 2025 06:00 | 3.88 | 5.47 | +41.0% | Beat |
| 01 May 2025 06:00 | 2.95 | 3.02 | +2.4% | Beat |
| 12 Feb 2025 07:00 | 3.36 | 3.44 | +2.3% | Beat |
| 30 Oct 2024 06:00 | 3.79 | 4.08 | +7.8% | Beat |
| 01 Aug 2024 06:00 | 4.03 | 5.28 | +31.0% | Beat |
| 24 Apr 2024 07:00 | 3.46 | 3.67 | +6.0% | Beat |
| 13 Feb 2024 07:00 | 3.18 | 2.95 | -7.2% | Miss |
| 08 Nov 2023 07:00 | 3.98 | 4.36 | +9.4% | Beat |
| 25 Jul 2023 07:00 | 3.76 | 4.02 | +6.9% | Beat |
| 25 Apr 2023 07:00 | 3.28 | 3.40 | +3.5% | Beat |
| 15 Feb 2023 07:00 | 3.48 | 4.05 | +16.2% | Beat |
| 25 Oct 2022 07:00 | 4.13 | 4.77 | +15.5% | Beat |
| 20 Jul 2022 07:00 | 4.07 | 5.25 | +29.0% | Beat |
| 03 May 2022 07:00 | 4.36 | 3.62 | -17.0% | Miss |
| 03 Feb 2022 07:00 | 3.37 | 3.39 | +0.6% | In line |
| 20 Oct 2021 07:00 | 4.10 | 4.77 | +16.5% | Beat |
| 22 Jul 2021 07:00 | 4.60 | 5.68 | +23.5% | Beat |
| 22 Apr 2021 07:00 | 4.94 | 5.34 | +8.1% | Beat |
| 03 Feb 2021 07:00 | 4.80 | 4.58 | -4.5% | Miss |
| 21 Oct 2020 07:00 | 8.05 | 8.84 | +9.8% | Beat |
| 22 Jul 2020 07:00 | 8.00 | 10.26 | +28.2% | Beat |
| 22 Apr 2020 07:00 | 7.69 | 9.14 | +18.9% | Beat |
| 30 Jan 2020 06:00 | 8.08 | 8.34 | +3.3% | Beat |
| 22 Oct 2019 07:00 | 8.27 | 9.17 | +10.8% | Beat |
| 23 Jul 2019 06:00 | 7.53 | 9.15 | +21.4% | Beat |
| 24 Apr 2019 06:00 | 6.96 | 6.98 | +0.3% | In line |
| 29 Jan 2019 06:00 | 6.72 | 6.99 | +4.0% | Beat |
| 23 Oct 2018 06:00 | 6.76 | 7.40 | +9.5% | Beat |
| 24 Jul 2018 06:00 | 5.14 | 5.80 | +12.7% | Beat |
| 24 Apr 2018 06:00 | 5.94 | 6.05 | +1.9% | Beat |
| 25 Jan 2018 06:00 | 5.45 | 5.26 | -3.5% | Miss |
| 24 Oct 2017 06:00 | 5.72 | 6.31 | +10.3% | Beat |
| 25 Jul 2017 06:00 | 4.37 | 5.04 | +15.3% | Beat |
| 25 Apr 2017 06:00 | 4.97 | 5.20 | +4.5% | Beat |
| 26 Jan 2017 06:00 | 4.96 | 5.04 | +1.6% | Beat |
| 26 Oct 2016 06:00 | 4.97 | 5.19 | +4.4% | Beat |
| 21 Jul 2016 07:00 | 4.69 | 5.21 | +11.2% | Beat |
| 21 Apr 2016 07:00 | 4.47 | 4.79 | +7.2% | Beat |
| 27 Jan 2016 07:00 | 4.08 | 4.50 | +10.3% | Beat |
| 21 Oct 2015 07:00 | 3.81 | 4.48 | +17.6% | Beat |
| 24 Jul 2015 06:00 | 4.09 | 4.22 | +3.1% | Beat |
| 24 Apr 2015 07:00 | 3.90 | 3.82 | -2.0% | Miss |
| 29 Jan 2015 16:00 | 3.77 | 4.09 | +8.4% | Beat |
| 22 Oct 2014 07:00 | 3.46 | 3.80 | +9.8% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 9.9B | +2.2% | 1.3B | 13.1% | 8.79 | -21.4% | 2B |
| 2024 | 9.7B | -1.6% | 1.6B | 16.9% | 11.18 | +40.3% | 2.5B |
| 2023 | 9.8B | -3.3% | 1.2B | 11.8% | 7.97 | -61.8% | 1.2B |
| 2022 | 10.2B | — | 3B | 29.9% | 20.87 | — | 1.1B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 253.81 | 261.00 | 240.00 | 251.60 | -0.80% | 9,656,739 | |
| Oct 2026 | 225.50 | 258.78 | 215.73 | 253.62 | +12.28% | 29,395,600 | |
| Sep 2026 | 218.11 | 230.49 | 208.93 | 225.88 | +4.26% | 21,431,600 | |
| Aug 2026 | 203.34 | 222.85 | 199.58 | 216.65 | +6.75% | 15,966,700 | |
| Jul 2026 | 215.25 | 219.02 | 186.03 | 202.95 | -6.07% | 31,695,000 | |
| Jun 2026 | 194.50 | 219.72 | 184.90 | 216.06 | +10.23% | 24,235,200 | |
| May 2026 | 189.28 | 205.97 | 185.44 | 196.00 | +3.55% | 22,250,400 | |
| Apr 2026 | 183.16 | 195.98 | 168.64 | 189.28 | +3.25% | 28,535,500 | |
| Mar 2026 | 190.22 | 192.99 | 171.37 | 183.33 | -4.43% | 21,907,700 | |
| Feb 2026 | 179.30 | 202.41 | 176.19 | 191.82 | +6.63% | 27,601,300 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Gene Therapy - Global Strategic Business Report: Capitalize on 23% CAGR as the Market Hits US$6 Billion by 2030; Benchmark Amgen, Alnylam, BioMarin, Biogen and bluebird bio (opens in a new tab) 11 Nov 2026 14:10
- Two Neighbors Will Start Leqembi, Listed at $28,270 a Year. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% of Medicare-Approved Infusion Costs (opens in a new tab) 24/7 Wall St. · 11 Nov 2026 01:03
- Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $305 (opens in a new tab) Benzinga · 09 Nov 2026 13:08
- UCB And Biogen Report Dapirolizumab Pegol Plus SOC Associated With Higher Response Versus Placebo On Novel TRM-SLE And Greater Sustained Low Disease Activity In Post-Hoc Phase 3 PHOENYCS GO Analyses (opens in a new tab) Benzinga · 09 Nov 2026 02:56
- Biogen’s (BIIB) Pipelines Offers Multiple Potential Catalysts (opens in a new tab) Insider Monkey · 05 Nov 2026 17:02
- Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone) (opens in a new tab) 05 Nov 2026 16:00
- Biogen Canada Announces Broad Private Drug Plan Coverage For ZURZUVAE, Expanding Access For Eligible Patients With Postpartum Depression In Adults Following Childbirth (opens in a new tab) Benzinga · 05 Nov 2026 12:06
- Is Alzheimer’s Data Altering The Investment Case For Biogen (BIIB)? (opens in a new tab) Simply Wall St. · 05 Nov 2026 09:13
- Guggenheim Maintains Buy on Biogen, Raises Price Target to $300 (opens in a new tab) Benzinga · 02 Nov 2026 10:29
- HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270 (opens in a new tab) Benzinga · 02 Nov 2026 08:06
- Biogen Swings Back to Growth as Stock Momentum Could Continue, RBC Says (opens in a new tab) MT Newswires · 29 Oct 2026 15:58
- Biogen (BIIB) Stock Price Tracks Q3 Results Through Loss And Cash Flow (opens in a new tab) Simply Wall St. · 29 Oct 2026 05:18
- Biogen Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 28 Oct 2026 22:04
- Biogen Has 'Returned To Growth,' Says CEO — What To Know About Its Report (opens in a new tab) Investor's Business Daily · 28 Oct 2026 20:09
- Biogen Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 28 Oct 2026 17:30
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 250.48 USD
- Market cap
- 37.3B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow BIIB and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.